Jack Khattar, Supernus CEO
October 11, 2021 10:00 AM EDTUpdated 10:14 AM
Financing
Deals

Su­per­nus ex­pands its port­fo­lio of Parkin­son's drugs with a $400M+ buy­out

Paul Schloesser

Associate Editor

Su­per­nus is mark­ing its ex­pan­sion in­to the Parkin­son’s dis­ease are­na, strik­ing a deal to buy out Adamas Phar­ma­ceu­ti­cals in a deal worth more than …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times